Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
NPJ Breast Cancer
|
March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 23, 2024
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
Eleonora Nicolò, Sara Gandini, Federica Giugliano, et al.
NPJ Breast Cancer
|
January 29, 2026
Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy
Luc Cabel, Julia Ah-Reum An, Hong-Kyu Kim, et al.
Breast (Edinburgh, Scotland)
|
May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Anna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)
Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Nature
|
March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
Anton Safonov, Minna Lee, David N Brown, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
NPJ Breast Cancer
|
March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 23, 2024
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
Eleonora Nicolò, Sara Gandini, Federica Giugliano, et al.
NPJ Breast Cancer
|
January 29, 2026
Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy
Luc Cabel, Julia Ah-Reum An, Hong-Kyu Kim, et al.
Breast (Edinburgh, Scotland)
|
May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Anna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)
Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Nature
|
March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
Anton Safonov, Minna Lee, David N Brown, et al.
Page
of 4